好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Frequency and Type of Pain Syndromes among NMOSD and MOGAD patients
Autoimmune Neurology
P4 - Poster Session 4 (8:00 AM-9:00 AM)
1-010

We examined the frequency and the type of pain syndromes in the published literature affecting MOGAD and NMOSD patients.

Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders (MOGAD) are autoimmune inflammatory disorders that affect the central nervous system. Pain is considered one of the debilitating symptoms that is highly prevalent and severely impairs the quality of life; however, the frequency and type of pain among them are still underreported. 

PubMed and Google Scholar databases searches were done through October 14, 2025, according to the PRISMA guidelines, using the following keywords (pain, neuropathic pain, ocular pain, headache, nociceptive pain, painful tonic spasm, spasticity-associated pain, MOGAD, Anti-myelin oligodendrocyte glycoprotein antibody-associated disorders, Neuromyelitis Optica Spectrum Disorder, NMOSD. Fourteen studies were included in our analysis.

Five hundred fifty-eight patients were included in our analysis. Five hundred ten patients were diagnosed with NMOSD, while 48 patients were diagnosed with MOGAD. The mean age of the patients in the MOGAD group was 32.2 ± 18.3 years, while the mean age of the NMOSD patients was 48.6 ± 4.37 years. Neuropathic pain was more common in the NMOSD compared to MOGAD (71% vs 43% p=0.01). Headache was the most common pain syndrome among MOGAD patients compared to NMOSD (45.83% vs 9.6%, p =0.01). No statistical difference in spasticity related pain between both groups (19.8% vs 31.25 % p=0.06). Similarly, pain due to other causes, such as arthralgia (11.3% 4.1%, p=0.12).

Pain is a frequent symptom in NMOSD and MOGAD. Pain syndromes differ between NMOSD and MOGAD, with a higher prevalence of headache in MOGAD and higher neuropathic pain in NMOSD. Further research should concentrate on a multidisciplinary approach to pain management focused on the respective pain type. 

Authors/Disclosures
Mahmoud Elkhooly, MD
PRESENTER
Dr. Elkhooly has nothing to disclose.
Arianna Di Stadio, MD, PhD Dr. Di Stadio has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Epitech. Dr. Di Stadio has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. The institution of Dr. Di Stadio has received research support from National Health Institute .
Muhammad M. Ismail, MD Dr. Ismail has nothing to disclose.
Amro E. AbuShanab, MBBS (SIU Neurology) Dr. AbuShanab has nothing to disclose.
Shashi K. Maryala, MBBS (Southern Illinois University Neuroscience Institute) Dr. Maryala has nothing to disclose.